49 related articles for article (PubMed ID: 38755645)
1. Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.
Lo YL; Li CY; Chou TF; Yang CP; Wu LL; Chen CJ; Chang YH
Biomed Pharmacother; 2024 Jun; 175():116660. PubMed ID: 38701563
[TBL] [Abstract][Full Text] [Related]
2. FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity.
Chen E; Wu J; Huang J; Zhu W; Sun H; Wang X; Lin D; Li X; Shi D; Liu Z; Huang J; Chen M; Xie F; Deng W
Nat Commun; 2024 May; 15(1):4590. PubMed ID: 38816360
[TBL] [Abstract][Full Text] [Related]
3. Ultra-small Janus nanoparticle-induced activation of ferroptosis for synergistic tumor immunotherapy.
Wang J; Wang Z; Li L; Wang M; Chang J; Gao M; Wang D; Li C
Acta Biomater; 2024 Jun; 181():362-374. PubMed ID: 38663684
[TBL] [Abstract][Full Text] [Related]
4. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.
An M; Mehta A; Min BH; Heo YJ; Wright SJ; Parikh M; Bi L; Lee H; Kim TJ; Lee SY; Moon J; Park RJ; Strickland MR; Park WY; Kang WK; Kim KM; Kim ST; Klempner SJ; Lee J
Cancer Discov; 2024 May; 14(5):766-785. PubMed ID: 38319303
[TBL] [Abstract][Full Text] [Related]
5. A pH/ROS dual-responsive system for effective chemoimmunotherapy against melanoma
Wang L; He S; Liu R; Xue Y; Quan Y; Shi R; Yang X; Lin Q; Sun X; Zhang Z; Zhang L
Acta Pharm Sin B; 2024 May; 14(5):2263-2280. PubMed ID: 38799639
[TBL] [Abstract][Full Text] [Related]
6. Microcystin-LR improves anti-tumor efficacy of oxaliplatin through induction of M1 macrophage polarization.
Li K; Yang M; Dai Y; Huang J; Zhu P; Qiuzhen L
Toxicon; 2024 May; 243():107723. PubMed ID: 38663519
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy.
Yang Y; Wang Y; Zeng F; Chen Y; Chen Z; Yan F
Cell Rep Med; 2024 May; 5(5):101512. PubMed ID: 38640931
[TBL] [Abstract][Full Text] [Related]
8. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy.
Ma B; Ma Y; Deng B; Xiao P; Huang P; Wang D; Liu L
J Nanobiotechnology; 2023 May; 21(1):171. PubMed ID: 37237292
[TBL] [Abstract][Full Text] [Related]
10. Augmenting Immunogenic Cell Death and Alleviating Myeloid-Derived Suppressor Cells by Sono-Activatable Semiconducting Polymer Nanopartners for Immunotherapy.
Ding M; Zhang Y; Yu N; Zhou J; Zhu L; Wang X; Li J
Adv Mater; 2023 Aug; 35(33):e2302508. PubMed ID: 37165741
[TBL] [Abstract][Full Text] [Related]
11. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.
Zhang H; Liu L; Liu J; Dang P; Hu S; Yuan W; Sun Z; Liu Y; Wang C
Mol Cancer; 2023 Mar; 22(1):58. PubMed ID: 36941614
[TBL] [Abstract][Full Text] [Related]
12. Tumor Therapy Strategies Based on Microenvironment-Specific Responsive Nanomaterials.
Zhang Z; Ding C; Sun T; Wang L; Chen C
Adv Healthc Mater; 2023 Aug; 12(20):e2300153. PubMed ID: 36933000
[TBL] [Abstract][Full Text] [Related]
13. Influenced tumor microenvironment and tumor immunity by amino acids.
Yu M; Zhang S
Front Immunol; 2023; 14():1118448. PubMed ID: 36798123
[TBL] [Abstract][Full Text] [Related]
14. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
Dubrot J; Du PP; Lane-Reticker SK; Kessler EA; Muscato AJ; Mehta A; Freeman SS; Allen PM; Olander KE; Ockerman KM; Wolfe CH; Wiesmann F; Knudsen NH; Tsao HW; Iracheta-Vellve A; Schneider EM; Rivera-Rosario AN; Kohnle IC; Pope HW; Ayer A; Mishra G; Zimmer MD; Kim SY; Mahapatra A; Ebrahimi-Nik H; Frederick DT; Boland GM; Haining WN; Root DE; Doench JG; Hacohen N; Yates KB; Manguso RT
Nat Immunol; 2022 Oct; 23(10):1495-1506. PubMed ID: 36151395
[TBL] [Abstract][Full Text] [Related]
15. The Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment.
Huang X; Zhang F; Wang X; Liu K
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681736
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.
Liu L; Huang X; Shi F; Song J; Guo C; Yang J; Liang T; Bai X
J Exp Clin Cancer Res; 2022 Feb; 41(1):56. PubMed ID: 35139879
[TBL] [Abstract][Full Text] [Related]
17. Nanovaccines with cell-derived components for cancer immunotherapy.
Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
[TBL] [Abstract][Full Text] [Related]
18. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
